Stocks analysis

ABT vs ADSK Stock Comparison

Scores Breakdown

Metric ABT ADSK
📈 Growth 22/30 28/30
💰 Profitability 17/20 18/20
🏦 Financial Health 15/20 12/20
💵 Valuation 12/20 12/20
⚠️ Risk (lower is better) 4/10 5/10
Overall Score 72/100 75/100

Side-by-Side Summaries

ABT Analysis ADSK Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (1.3–1.5) and modest long-term debt ($14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

  • Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
  • Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from roughly $1.50B to $1.93B, and Net Income grew from about $275M to $491M, delivering a clear top‑ and bottom‑line uptrend. The sequence shows steady sequential gains with only modest quarterly volatility, translating to ~29% revenue growth and ~78% net income growth across the period.

💰 Margins & Cash Flow

Gross margins run in the mid‑to‑high 80s percent range, with Gross Profit margin staying strong relative to Revenues. Operating leverage appears favorable as operating income remains healthy while R&D and other investments persist. Cash flow from operations is consistently positive, often in the hundreds of millions (e.g., ~$460–$564M), with occasional financing outflows; investing cash flow is modest and generally supportive of ongoing growth.

🛡️ Balance Sheet & Liquidity

Total assets hover around $9.5–11B and long‑term debt sits near $2.3–2.5B, yielding a balance sheet with solid equity (around $2.5–3.1B). Current liabilities and assets are balanced enough to sustain operations, providing resilience through moderate liquidity headroom.

⚠️ Key Drivers & Risks

  • Drivers: AI-enabled design features and expanding cloud adoption.
  • Risks: Valuation sensitivity to multiples and near‑term liquidity headroom pressures from financing activities.